Christine previously served as the SVP, Chief Operating Officer for US Generics and Global Biosimilars at Teva Pharmaceuticals. Christine served in the US Generic leadership team for Teva for 15 years, where she held multiple positions across the commercial organization including most recently the addition of biosimilar. She held full P& L accountability for the US Generic market since 2018. Prior to joining Teva, Christine served on Sandoz US generic team where she developed a deep expertise in the importance of cross functional alignment between commercial and operations. Christine also supported Teva brand portfolio with supply chain and launch support.
Christine has served as on Association for Accessible Medicines (AAM) since 2022. She was elected chair in 2023. She has a BS degree in Biology for Wright State University in Dayton, OH and an MBA from Fuqua School at Duke, Durham, NC
